Dr. Stahl was born in Detroit, Michigan and spent much of his childhood wondering how the mind works. With a strong early interest in neuroscience, he moved to Miami at the age of 17 to pursue undergraduate studies in biochemistry and psychology at the University of Miami. His research career began during his junior year when he joined the lab of Dr. Claudia Rodrigues to investigate the role of endothelial dysfunction on neuroinflammation. After earning a dual degree, Dr. Stahl continued his scientific training in the lab of Dr. Claes Wahlestedt at the University of Miami’s Center for Therapeutic Innovation where he completed a PhD in neuroscience. With a personal motive to develop a disease-modifying therapeutic for Alzheimer’s Disease, Dr. Stahl’s dissertation work was focused on developing multi-targeting oligonucleotide therapeutics for Alzheimer’s Disease and other neurological disorders. His work resulted in the formation of a biotechnology company, Tinker Therapeutics, which was awarded the first-place prize in Eli Lilly’s Genetic Medicine Grand Challenge in 2024. Today, Dr. Stahl is continuing his work on therapeutic development as a CrossROADS T32 postdoctoral scholar under the mentorship of Dr. Wahlestedt, and Dr. Tatjana Rundek with an ongoing focus on treatments for Alzheimer’s Disease and other neurological disorders.